<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00599911</url>
  </required_header>
  <id_info>
    <org_study_id>11918A</org_study_id>
    <secondary_id>2007-001071-11</secondary_id>
    <nct_id>NCT00599911</nct_id>
  </id_info>
  <brief_title>Dose-finding Study With Lu AA24530 in Major Depressive Disorder</brief_title>
  <official_title>Randomised, Double-blind, Parallel-group, Placebo-controlled, Active-referenced, Dose-finding Study of Lu AA24530 in Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the efficacy in treating patients with Major
      Depressive Disorder of one or more doses of Lu AA24530 relative to placebo
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the World Health Organisation, Major Depressive Disorder is the leading cause of
      disability and the 4th leading contributor to the global burden of disease. There are unmet
      medical needs in the treatment of depressive disorders in terms of insufficient effectiveness
      and unpleasant side-effects of current therapies. The overall prognosis of the disorder is
      positive for the majority of patients, but as many as 30% of patients will develop a chronic
      and treatment-resistant depression. In the study, patients with depression are treated for 6
      weeks. Assessments of efficacy and safety are taking place every week for the first 4 weeks
      and again after 6 weeks of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference in change from baseline to end of treatment on the Montgomery-Ã…sberg Depression Rating Scale total score</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate, remission rate, and safety</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">652</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Lu AA24530: 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lu AA24530: 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lu AA24530: 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Duloxetine: 60 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AA24530</intervention_name>
    <description>per oral, once daily for 6 weeks</description>
    <arm_group_label>Lu AA24530: 5 mg</arm_group_label>
    <arm_group_label>Lu AA24530: 10 mg</arm_group_label>
    <arm_group_label>Lu AA24530: 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>per oral, once daily for 6 weeks</description>
    <arm_group_label>Duloxetine: 60 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>per oral, once daily for 6 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Major Depressive Episode that has lasted at least 3 months

          -  Moderate to severe depression

        Exclusion Criteria:

          -  Any current psychiatric disorder established as the principal diagnosis other than MDD
             as defined in the DSM-IV-TR and as assessed with the Mini-International
             Neuropsychiatric Interview (MINI)

          -  Current or past history of: manic or hypomanic episode, schizophrenia or any other
             psychotic disorder, including major depression with psychotic features, mental
             retardation, organic mental disorders, or mental disorders due to a general medical
             condition as defined in the DSM-IV-TR

          -  Major Depressive Episode that has been unresponsive to two adequate courses of
             antidepressant treatment, each of at least 6 weeks duration

          -  Electroconvulsive therapy within 6 months prior to Baseline

          -  Ongoing formal cognitive or behavioural therapy, systematic psychotherapy, or plans to
             initiate such therapy during the study

          -  Clinically significant unstable illness, for example, hepatic or renal insufficiency,
             or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, infectious,
             neoplastic, or metabolic disturbance

          -  The patient is pregnant or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AU002</name>
      <address>
        <city>Brisbane</city>
        <zip>4000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AU001</name>
      <address>
        <city>Brisbane</city>
        <zip>4053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AU003</name>
      <address>
        <city>Dandenc</city>
        <zip>3175</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AU004</name>
      <address>
        <city>Epping</city>
        <zip>3076</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AU006</name>
      <address>
        <city>Malvern</city>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AT001</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AT002</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AT003</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BE003</name>
      <address>
        <city>Diest</city>
        <zip>2930</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BE002</name>
      <address>
        <city>Sint-Niklaas</city>
        <zip>9100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CA006</name>
      <address>
        <city>Mississauga</city>
        <zip>L5M 4N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CA004</name>
      <address>
        <city>Oakville</city>
        <zip>L6J 7W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CA003</name>
      <address>
        <city>Penticton</city>
        <zip>V2A 4M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CA005</name>
      <address>
        <city>Toronto</city>
        <zip>M4S 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CA001</name>
      <address>
        <city>Vancouver</city>
        <zip>V6Z 2L4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CZ002</name>
      <address>
        <city>Brno</city>
        <zip>60200</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CZ005</name>
      <address>
        <city>Praha 2</city>
        <zip>12000</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CZ001</name>
      <address>
        <city>Praha 5</city>
        <zip>15030</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CZ004</name>
      <address>
        <city>Praha 5</city>
        <zip>158 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CZ003</name>
      <address>
        <city>Praha 6</city>
        <zip>16000</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CZ006</name>
      <address>
        <city>Sternberk</city>
        <zip>78517</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FI001</name>
      <address>
        <city>Helsinki</city>
        <zip>00260</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FI003</name>
      <address>
        <city>Helsinki</city>
        <zip>00530</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FI006</name>
      <address>
        <city>JÃ¤rvenpÃ¤Ã¤</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FI004</name>
      <address>
        <city>SeinÃ¤joki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FI005</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FI002</name>
      <address>
        <city>Turku</city>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR007</name>
      <address>
        <city>Angouleme</city>
        <zip>16000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR002</name>
      <address>
        <city>Dole</city>
        <zip>39100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR003</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR001</name>
      <address>
        <city>Orvault</city>
        <zip>44700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR008</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR004</name>
      <address>
        <city>Savigny sur Orge</city>
        <zip>91600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR005</name>
      <address>
        <city>Wattigny</city>
        <zip>59139</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IN001</name>
      <address>
        <city>Ahmedabab</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IN009</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IN007</name>
      <address>
        <city>Chennai</city>
        <zip>3</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IN006</name>
      <address>
        <city>Hyderabaad</city>
        <zip>500 034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IN003</name>
      <address>
        <city>Mangalore</city>
        <zip>574160</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IN002</name>
      <address>
        <city>Pune</city>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KR003</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KR002</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KR001</name>
      <address>
        <city>Seoul</city>
        <zip>138-746</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LT002</name>
      <address>
        <city>Kaunas</city>
        <zip>50185</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LT003</name>
      <address>
        <city>Klaipeda</city>
        <zip>91251</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LT001</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MY002</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>55100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MY003</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NO004</name>
      <address>
        <city>Fredrikstad</city>
        <zip>1606</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NO001</name>
      <address>
        <city>Hamar</city>
        <zip>2315</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NO003</name>
      <address>
        <city>Skien</city>
        <zip>3725</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PH002</name>
      <address>
        <city>Las Pinas</city>
        <zip>1701</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PH003</name>
      <address>
        <city>Mandaluyong City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PH001</name>
      <address>
        <city>Mandaue City</city>
        <zip>6014</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU005</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163061</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU002</name>
      <address>
        <city>Nikolskoe</city>
        <zip>188357</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU004</name>
      <address>
        <city>Saratov</city>
        <zip>410028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU003</name>
      <address>
        <city>St-Petersburg</city>
        <zip>190005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU001</name>
      <address>
        <city>Tomsk</city>
        <zip>634014</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RS004</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RS002</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SE006</name>
      <address>
        <city>Halmstad</city>
        <zip>301 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SE001</name>
      <address>
        <city>LinkÃ¶ping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SE002</name>
      <address>
        <city>Lund</city>
        <zip>223 61</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SE003</name>
      <address>
        <city>MalmÃ¶</city>
        <zip>21237</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SE005</name>
      <address>
        <city>Stockholm</city>
        <zip>112 34</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SE004</name>
      <address>
        <city>Uppsala</city>
        <zip>753 19</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UA003</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UA005</name>
      <address>
        <city>Kharkov</city>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UA002</name>
      <address>
        <city>Kyiv</city>
        <zip>4080</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UA004</name>
      <address>
        <city>Lviv</city>
        <zip>79021</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UA001</name>
      <address>
        <city>Odessa</city>
        <zip>65006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Norway</country>
    <country>Philippines</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Sweden</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2007</study_first_submitted>
  <study_first_submitted_qc>January 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2008</study_first_posted>
  <last_update_submitted>November 7, 2016</last_update_submitted>
  <last_update_submitted_qc>November 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <keyword>Depressive disorder</keyword>
  <keyword>Antidepressive agents</keyword>
  <keyword>Depressive symptoms</keyword>
  <keyword>Affective disorders</keyword>
  <keyword>Randomized controlled trial</keyword>
  <keyword>Placebo-controlled</keyword>
  <keyword>Double-blind</keyword>
  <keyword>Active reference</keyword>
  <keyword>Multicenter study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_id>2007-001071-11</doc_id>
      <doc_type>EMA EudraCT Results</doc_type>
      <doc_url>https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-001071-11/results</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

